Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Diabetes drug shows promise for obesity after brain tumor therapy

NCT ID NCT02860923

First seen May 15, 2026 · Last updated May 19, 2026 · Updated 1 time

Summary

This study tested whether the diabetes drug exenatide can help adults with severe weight gain caused by treatment for a rare brain tumor called craniopharyngioma. 42 participants received either exenatide or a placebo, along with lifestyle advice, for 6 months. The main goal was to see if exenatide leads to more weight loss than placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOTHALAMIC OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • APHM

    Marseille, France

  • CHU d'Angers

    Angers, France

  • CHU de Brest

    Brest, France

  • CHU de Grenoble

    Grenoble, France

  • CHU de Lyon

    Lyon, France

  • CHU de Toulouse

    Toulouse, France

  • Hôpital Bicêtre

    Paris, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Européen Georges Pompidou

    Paris, France

  • Hôpital Haut-Lévêque

    Pessac, France

  • Hôpital Pitié Salpétrière (APHP)

    Paris, France

Conditions

Explore the condition pages connected to this study.